Zielinski RR, Azad AA, Chi KN, Tyldesley S. Population-based impact on overall survival after the introduction of docetaxel as standard therapy for metastatic castration resistant prostate cancer. CUAJ [Internet]. 2014 Aug. 11 [cited 2024 Apr. 24];8(7-8):e520-3. Available from: https://cuaj.ca/index.php/journal/article/view/2076